Bisphosphonate treatment in inaccessible osteoid osteomas: An alternative therapeutic approach.

Autor: Larid G; Rheumatology Department, Sainte-Marguerite Hospital, AP-HM, 13009 Marseille, France; Rheumatology Department, Poitiers University Hospital, 86000 Poitiers, France; LITEC Laboratory, University of Poitiers, 86000 Poitiers, France. Electronic address: guillaume.larid@chu-poitiers.fr., Valayer S; Internal Medicine Department, Cochin Hospital, Paris, France., Jacquier C; Internal Medicine and Rheumatology Department, Percy Military Teaching Hospital, 92141 Clamart, France., Lafforgue P; Rheumatology Department, Sainte-Marguerite Hospital, AP-HM, 13009 Marseille, France; Aix-Marseille University, 13284 Marseille, France., Laredo JD; Paris Cité University, 75013 Paris, France; Orthopaedic and Trauma Surgery, Lariboisière Hospital, AP-HP, 75010 Paris, France., Pham T; Rheumatology Department, Sainte-Marguerite Hospital, AP-HM, 13009 Marseille, France; Aix-Marseille University, 13284 Marseille, France.
Jazyk: angličtina
Zdroj: Joint bone spine [Joint Bone Spine] 2023 Dec; Vol. 90 (6), pp. 105589. Date of Electronic Publication: 2023 May 16.
DOI: 10.1016/j.jbspin.2023.105589
Abstrakt: Introduction: Osteoid osteoma is a benign osteogenic tumour traditionally treated by surgical excision or percutaneous CT-guided procedures. We describe three cases of osteoid osteomas of which the locations were difficult to access, or for which the procedure was potentially unsafe, involving treatment with zoledronic acid infusions.
Case Description: We report here three male 28-to-31-year-old patients with no medical history who had osteoid osteomas located at the second cervical vertebra, the femoral head, and the third lumbar vertebra respectively. These lesions were responsible for inflammatory pain requiring daily treatment with acetylsalicylic acid. Given the impairment risk, all of the lesions were ineligible for surgical or percutaneous treatment. Patients were successfully treated by 3 to 6 monthly zoledronic acid infusions. All patients experienced complete relief of their symptoms allowing aspirin discontinuation, without any side effects. In the first two cases, CT and MRI control showed nidus mineralization and bone marrow oedema regression, correlating with the pain decrease. After 5years of follow-up, there had been no recurrence of the symptoms.
Conclusion: In these patients, monthly 4mg zoledronic acid infusions have been safe and effective in the treatment of inaccessible osteoid osteomas.
(Copyright © 2023 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: